Overcoming Pharma’s Major Pain Points and Pitfalls With AI
This technological shift not only boosts efficiency and profitability for pharmaceutical companies but also speeds up the delivery of innovative therapies to patients.
Dave Latshaw II
Dave Latshaw II, Ph.D. M.B.A., is a multidisciplinary expert with extensive experience in artificial intelligence, biotechnology, and business innovation. He specializes in bridging these fields to address complex challenges in research and development. Dave began his journey in biotechnology at North Carolina State University, where he earned his Ph.D. in chemical and biomolecular engineering, studying neurodegenerative diseases through computational biophysics and machine learning.
Upon graduating, Dave joined Johnson & Johnson's Advanced Technologies Center of Excellence as the youngest person to lead flagship AI programs. Dave’s technology was pivotal in J&J's commitment to providing a billion doses during the Covid-19 pandemic, enabling rapid scale-up of the novel manufacturing process. Recognizing larger-scale inefficiencies in drug development, Dave pursued his MBA at Wharton Business School, where he conceived the idea for BioPhy, a life sciences health tech company founded in 2020.